145 related articles for article (PubMed ID: 37001283)
1. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies.
Elhadad S; Redmond D; Tan A; Huang J; Rodriguez BL; Racine-Brzostek SE; Subrahmanian S; Ahamed J; Laurence J
Thromb Res; 2023 May; 225():47-56. PubMed ID: 37001283
[TBL] [Abstract][Full Text] [Related]
2. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
Elhadad S; Chapin J; Copertino D; Van Besien K; Ahamed J; Laurence J
Clin Exp Immunol; 2021 Jan; 203(1):96-104. PubMed ID: 32681658
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
Higham CS; Shimano KA; Melton A; Kharbanda S; Chu J; Dara J; Winestone LE; Hermiston ML; Huang JN; Dvorak CC
Pediatr Blood Cancer; 2022 May; 69(5):e29641. PubMed ID: 35253361
[TBL] [Abstract][Full Text] [Related]
4. Role of transforming growth factor beta1 in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.
Mauro M; Kim J; Costello C; Laurence J
Am J Hematol; 2001 Jan; 66(1):12-22. PubMed ID: 11426486
[TBL] [Abstract][Full Text] [Related]
5. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.
Mauro M; Zlatopolskiy A; Raife TJ; Laurence J
Br J Haematol; 2004 Jan; 124(2):200-10. PubMed ID: 14687031
[TBL] [Abstract][Full Text] [Related]
6. Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Gloude NJ; Jodele S; Teusink-Cross A; Grimley M; Davies SM; Lane A; Myers KC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):91-95. PubMed ID: 28939456
[TBL] [Abstract][Full Text] [Related]
7. The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae.
Richardson PG; Palomo M; Kernan NA; Hildebrandt GC; Chao N; Carreras E
Bone Marrow Transplant; 2021 Dec; 56(12):2889-2896. PubMed ID: 34584241
[TBL] [Abstract][Full Text] [Related]
8. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.
Elhadad S; Redmond D; Huang J; Tan A; Laurence J
Clin Exp Immunol; 2023 Jul; 213(2):252-264. PubMed ID: 37191586
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
10. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
11. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
[TBL] [Abstract][Full Text] [Related]
13. Endothelial cell apoptotic genes associated with the pathogenesis of thrombotic microangiopathies: an application of oligonucleotide genechip technology.
Kim J; Wu H; Hawthorne L; Rafii S; Laurence J
Microvasc Res; 2001 Sep; 62(2):83-93. PubMed ID: 11516238
[TBL] [Abstract][Full Text] [Related]
14. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
15. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
Keating GM
Clin Drug Investig; 2014 Dec; 34(12):895-904. PubMed ID: 25351934
[TBL] [Abstract][Full Text] [Related]
17. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.
Aziz MT; Kakadiya PP; Kush SM; Weigel K; Lowe DK
Ann Pharmacother; 2018 Feb; 52(2):166-174. PubMed ID: 28914546
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
20. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
